Pharmaceuticals & Therapeutics

As automation demand soars, ATS Corp. will meet investors to outline its strategy for navigating market shifts and capitalizing on life sciences growth.

The telehealth giant is launching a new vertical for healthy aging, aiming to fix a market that has historically ignored women's specific biological needs.

In the quest to drug the 'undruggable,' Erasca consolidates worldwide control of its promising pan-RAS inhibitor, setting the stage for a global showdown.

Promising results for bladder cancer therapy TARA-002, key FDA designations, and a $198M cash runway position Protara for a pivotal year.

A new campaign by Palvella Therapeutics and key partners aims to educate and empower patients with a rare disease, a strategic move ahead of a potential new drug.

With its novel glaucoma drug QLS-111 entering Phase 3, Qlaris Bio brings in seasoned leader Fred Guerard to navigate the final trials and path to market.

A new drug targeting the root cause of deadly device infections enters a pivotal trial, offering hope to millions and challenging a $20 billion problem.

Edgewise Therapeutics' drug sevasemten shows unprecedented functional stability in Becker muscular dystrophy, a pivotal shift for a disease with no treatments.

After selling assets and raising cash, Q32 Bio focuses all its resources on bempikibart, a novel drug for hair loss, with pivotal data due in 2026.

K-pop sensation Kim Sejeong is the new face of REJURAN, a move merging celebrity appeal with advanced skin science to expand K-beauty's global reach.

Relmada Therapeutics stock skyrockets on promising bladder cancer data and a $160M financing deal, setting a high-stakes stage for its investor conference.

AEON Biopharma hires a seasoned CFO to navigate FDA trials and financial hurdles as it aims to launch its BOTOX biosimilar into a lucrative market.

A large-scale analysis reveals that tenapanor, known as IBSRELA, provides quicker relief from constipation and abdominal pain for adults with IBS-C.

Emalex Biosciences offers its investigational drug ecopipam to Tourette syndrome patients out of options, signaling a potential shift in treatment.

A massive investment in Kankakee promises hundreds of jobs and a vital increase in life-saving plasma therapies for patients with rare diseases.

A landmark European approval for Elfabrio allows stable Fabry disease patients to switch to monthly infusions, promising greater freedom and lower healthcare strain.

A new drug, CRS3123, not only cures C. difficile but drastically cuts recurrence rates by preserving the gut microbiome, a major leap over standard care.

A year after rebranding from FibroGen, Kyntra Bio's first full-year report will test if its lean strategy can fuel its ambitious oncology pipeline.

A strategic partnership with Tenacia gives Rapport's novel CNS drug, RAP-219, a path into Greater China, backed by strong Phase 2 data and non-dilutive funding.

A new study finds Reiki therapy doesn't reduce pre-surgery anxiety for wisdom tooth removal, but it may offer a slight edge in postoperative pain.